HMGB1 in Hormone-Related Cancer: a Potential Therapeutic Target

被引：27

作者：

Srinivasan, Madhuwanti ^{[1
]}

Banerjee, Souresh ^{[1
]}

Palmer, Allison ^{[1
]}

Zheng, Guoxing ^{[1
]}

Chen, Aoshuang ^{[1
]}

Bosland, Maarten C. ^{[2
]}

Kajdacsy-Balla, Andr ^{[2
]}

Kalyanasundaram, Ramaswamy ^{[1
]}

Munirathinam, Gnanasekar ^{[1
,3
]}

机构：

[1] Univ Illinois, Coll Med, Dept Biomed Sci, Rockford, IL 61107 USA

[2] Univ Illinois, Dept Pathol, Chicago, IL USA

[3] Univ Illinois, Ctr Canc, Chicago, IL USA

来源：

HORMONES & CANCER | 2014年 / 5卷 / 03期

关键词：

MOBILITY GROUP BOX-1; END-PRODUCTS RAGE; DNA-BINDING; CELL-DEATH; PROGESTERONE-RECEPTOR; CHROMATIN PROTEINS; MESSENGER-RNA; LETHAL SEPSIS; CALF-THYMUS; BETA-CELLS;

D O I：

10.1007/s12672-014-0175-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

High-mobility group box 1 (HMGB1) is a dynamic nuclear protein participating in transcription, chromatin remodelling, and DNA recombination and repair processes. Accumulating evidence indicates that its function now extends beyond the nucleus, notably its extracellular role in inflammation. HMGB1 is implicated as a late mediator of sepsis and is also believed to promote atherosclerosis and other inflammatory diseases such as rheumatoid arthritis and systemic lupus erythematosus. Interestingly, deregulation of HMGB1 is shown to be associated with the hallmarks of cancer development. Moreover, several clinical studies have shown that HMGB1 is a promising biomarker for a variety of cancer types. In this review, we provide novel insights into the role and mechanisms of HMGB1, in particular, to hormone-related cancers and its potential to serve as a therapeutic target.

引用

页码：127 / 139

页数：13

共 50 条

[1] HMGB1 as a Potential Biomarker and Therapeutic Target for Malignant Mesothelioma
Wang, Yanbin
Jiang, Zhaoqiang
Yan, Jianing
Ying, Shibo
DISEASE MARKERS, 2019, 2019
[2] An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies
Musumeci, Domenica
Roviello, Giovanni N.
Montesarchio, Daniela
PHARMACOLOGY & THERAPEUTICS, 2014, 141 (03) : 347 - 357
[3] HMGB1 as a potential biomarker and therapeutic target for severe COVID-19
Chen, Ruochan
Huang, Yan
Quan, Jun
Liu, Jiao
Wang, Haichao
Billiar, Timothy R.
Lotze, Michael T.
Zeh, Herbert J.
Kang, Rui
Tang, Daolin
HELIYON, 2020, 6 (12)
[4] Extracellular HMGB1 as a therapeutic target in inflammatory diseases
Andersson, Ulf
Yang, Huan
Harris, Helena
EXPERT OPINION ON THERAPEUTIC TARGETS, 2018, 22 (03) : 263 - 277
[5] HMGB1 Is a Therapeutic Target for Sterile Inflammation and Infection
Andersson, Ulf
Tracey, Kevin J.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 : 139 - 162
[6] HMGB1 protein as a novel target for cancer
Tripathi, Alok
Shrinet, Kriti
Kumar, Arvind
TOXICOLOGY REPORTS, 2019, 6 : 253 - 261
[7] Review: Therapeutic Targeting of HMGB1 in Stroke
Tian, Xiaodi
Liu, Chenglin
Shu, Zhang
Chen, Gang
CURRENT DRUG DELIVERY, 2017, 14 (06) : 785 - 790
[8] High Mobility Group Box 1 (HMGB1): Molecular Signaling and Potential Therapeutic Strategies
Datta, Sayantap
Rahman, Mohammad Atiqur
Koka, Saisudha
Boini, Krishna M.
CELLS, 2024, 13 (23)
[9] Glycodelin in reproductive endocrinology and hormone-related cancer
Seppala, M.
Koistinen, H.
Koistinen, R.
Hautala, L.
Chiu, P. C.
Yeung, W. S.
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2009, 160 (02) : 121 - 133
[10] Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis
Kaur, Ishnoor
Behl, Tapan
Bungau, Simona
Kumar, Arun
Mehta, Vineet
Setia, Dhruv
Uddin, Sahab
Zengin, Gokhan
Aleya, Lotfi
Arora, Sandeep
LIFE SCIENCES, 2020, 258

← 1 2 3 4 5 →